CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2017	Sep. 30, 2016
Operating activities
Net income		$ 170,544	$ 179,540
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation		173,378	154,308
Amortization of intangible and other assets and favorable/unfavorable leases		1,167	1,566
Amortization of long-term prepaid rents		1,540	1,357
Amortization of debt issue costs		4,619	4,068
Amortization of deferred revenues, deferred lease incentives and other		(12,037)	(13,017)
Impairment of long-lived assets		9,600	2,323
Share based awards compensation expense		9,487	10,247
Loss on sale of assets and other		9,464	10,985
Write-off of unamortized debt issue costs associated with early retirement of debt		0	2,369
Deferred lease expenses		(1,019)	(809)
Equity in income of affiliates		(26,767)	(24,597)
Deferred income tax expenses		9,541	16,382
Distributions from equity investees	[1]	17,321	9,660
Changes in assets and liabilities and other		(55,433)	(76,102)
Net cash provided by operating activities		311,405	278,280
Investing activities
Additions to theatre properties and equipment and other		(262,730)	(230,346)
Acquisitions of theatres in the U.S. and international markets		(41,000)	(15,300)
Proceeds from sale of theatre properties and equipment and other		14,816	3,398
Proceeds from sale of marketable securities		0	13,451
Investment in joint ventures and other		(1,178)	(1,703)
Net cash used for investing activities		(290,092)	(230,500)
Financing activities
Dividends paid to stockholders		(101,304)	(94,117)
Payroll taxes paid as a result of restricted stock withholdings		(2,943)	(6,828)
Proceeds from issuance of Senior Notes, net of discount		0	222,750
Retirement of Senior Subordinated Notes		0	(200,000)
Repayments of long-term debt		(2,855)	(15,217)
Payment of debt issue costs		(817)	(4,504)
Payments on capital leases		(15,814)	(14,655)
Proceeds from financing lease		10,200	0
Other		(620)	1,282
Net cash used for financing activities		(114,153)	(111,289)
Effect of exchange rate changes on cash and cash equivalents		1,051	2,081
Decrease in cash and cash equivalents		(91,789)	(61,428)
Cash and cash equivalents:
Beginning of period		561,235	588,539
End of period		$ 469,446	$ 527,111

[1] Includes cash distributions received from equity investees that were recorded as a reduction of the respective investment balances (see Notes 6 and 7). These distributions are reported entirely within the U.S. operating segment.